PMV Pharmaceuticals, Inc. (PMVP) stock
Close on Nov 12, 2026Market cap $64.68MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $64.68M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.13
- Dividend yield
- –
- Free cash flow yield
- -107.67%
Fundamentals
- Net income
- -$88.53M
- EPS, diluted
- -$1.54
- Free cash flow
- -$69.64M
- Book value per share
- $0.86
- Diluted shares
- 66M
Trading
- Next earnings
- Mar 5, 2027 (estimated, before the open)
- Previous close
- $1.26
- Open
- $1.25
- Day's range
- $1.18 – $1.27
- Volume
- 353,447
- Average volume (20 days)
- 382,057
- Beta (5 years)
- 1.11
- 52-week range
- $1.02 – $1.91
- RSI (14 days)
- 42.4
- Volatility (1 year)
- 72.1%
- Relative volume
- 0.60×
- WACC
- 10.5%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | PMVP | S&P 500 | Difference | PMVP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -14.2% | -2.7% | −11.5 pts | ||
| 3 months | -4.0% | -1.7% | −2.2 pts | ||
| Year to date | -3.2% | +11.9% | −15.1 pts | ||
| 1 year | -14.8% | +12.0% | −26.8 pts | ||
| 3 years | -39.5% | +78.2% | −117.7 pts | -15.4% | +21.2% |
| 5 years | -95.0% | +73.2% | −168.3 pts | -45.1% | +11.6% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases PMV Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- News
- News
- Results
- Results
About PMV Pharmaceuticals
Pharmaceutical Preparations
PMV Pharmaceuticals is a precision oncology company that discovers and develops small molecule, tumor-agnostic therapies targeting mutant p53 proteins to restore their normal tumor-suppressing function. The company's lead product candidate is rezatapopt, an orally administered small molecule designed to structurally correct misfolded p53 proteins carrying the Y220C mutation. Rezatapopt aims to treat patients with advanced or metastatic solid tumors harboring this mutation, including ovarian, endometrial, breast, non-small cell lung, colorectal, and pancreatic cancers.
Company profile, executives and historyPMV Pharmaceuticals stock: common questions
What is PMV Pharmaceuticals's stock price?
PMVP closed at $1.21 on Nov 12, 2026, down 3.97% on the day. Over the past 52 weeks it traded between $1.02 and $1.91.
What is PMV Pharmaceuticals's market cap?
PMV Pharmaceuticals was worth $64.68M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is PMVP's P/E ratio?
PMV Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.54), so it has no meaningful P/E ratio.
Does PMV Pharmaceuticals pay a dividend?
No. PMV Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does PMV Pharmaceuticals report earnings next?
PMV Pharmaceuticals is expected to report Q4 FY2026 results on Mar 5, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has PMVP stock performed over the past year?
Including dividends, PMVP returned -14.8% over the past year, against +12.0% for the S&P 500.
How many PMVP shares are sold short?
2M shares were sold short at the latest FINRA report, 5.26% of the float, or 5.6 days of average trading volume.
Who are PMV Pharmaceuticals's competitors?
Companies most similar to PMV Pharmaceuticals by business, industry and size include PRLD, TNGX, LSTA, APRE, IDYA.
See a number that looks wrong?